Bachem Increases Sales and Profitability
Bachem (SIX: BANB) reported strong financial results for 2024, with group sales increasing 4.8% to CHF 605.3 million and EBITDA rising 5.7% to CHF 176.3 million. The company achieved an EBITDA margin of 29.1% and net income growth of 7.5% to CHF 120.2 million.
Sales performance across categories showed positive momentum: Commercial API sales grew 5.8% to CHF 327.0 million, CMC Development increased 3.0% to CHF 234.4 million, and Research & Specialties rose 7.5% to CHF 43.8 million.
The company invested CHF 292.2 million in capacity expansion in 2024, including progress on building 'K' in Bubendorf, set to begin test batch production in Q2 2025. Bachem targets 10-15% growth in local currencies for 2025, with planned CAPEX investments exceeding CHF 400 million. The company aims to achieve annual sales of over CHF 1 billion with an EBITDA margin above 30% by 2026.
Bachem (SIX: BANB) ha riportato risultati finanziari solidi per il 2024, con vendite di gruppo in aumento del 4,8% a CHF 605,3 milioni e un EBITDA in crescita del 5,7% a CHF 176,3 milioni. L'azienda ha raggiunto un margine EBITDA del 29,1% e una crescita dell'utile netto del 7,5% a CHF 120,2 milioni.
Le performance di vendita per categoria hanno mostrato un andamento positivo: le vendite di API commerciali sono aumentate del 5,8% a CHF 327,0 milioni, lo sviluppo CMC è cresciuto del 3,0% a CHF 234,4 milioni e Ricerca & Specialità è aumentato del 7,5% a CHF 43,8 milioni.
L'azienda ha investito CHF 292,2 milioni nell'espansione della capacità nel 2024, compresi i progressi nella costruzione di 'K' a Bubendorf, che dovrebbe iniziare la produzione di test batch nel secondo trimestre del 2025. Bachem punta a una crescita del 10-15% in valute locali per il 2025, con investimenti CAPEX pianificati superiori a CHF 400 milioni. L'azienda mira a raggiungere vendite annuali superiori a CHF 1 miliardo con un margine EBITDA superiore al 30% entro il 2026.
Bachem (SIX: BANB) reportó resultados financieros sólidos para 2024, con ventas del grupo aumentando un 4,8% a CHF 605,3 millones y un EBITDA que creció un 5,7% a CHF 176,3 millones. La compañía logró un margen EBITDA del 29,1% y un crecimiento del ingreso neto del 7,5% a CHF 120,2 millones.
El desempeño de ventas en las categorías mostró un impulso positivo: las ventas de API comerciales crecieron un 5,8% a CHF 327,0 millones, el desarrollo CMC aumentó un 3,0% a CHF 234,4 millones y la Investigación & Especialidades subió un 7,5% a CHF 43,8 millones.
La compañía invirtió CHF 292,2 millones en expansión de capacidad en 2024, incluidos los avances en la construcción de 'K' en Bubendorf, que comenzará la producción de lotes de prueba en el segundo trimestre de 2025. Bachem tiene como objetivo un crecimiento del 10-15% en monedas locales para 2025, con inversiones CAPEX planificadas que superan los CHF 400 millones. La empresa busca alcanzar ventas anuales de más de CHF 1 mil millones con un margen EBITDA superior al 30% para 2026.
바켐 (SIX: BANB)은 2024년 강력한 재무 결과를 보고했으며, 그룹 매출은 4.8% 증가하여 CHF 605.3 백만에 이르고, EBITDA는 5.7% 증가하여 CHF 176.3 백만에 도달했습니다. 회사는 29.1%의 EBITDA 마진과 7.5%의 순이익 증가를 기록하여 CHF 120.2 백만에 도달했습니다.
카테고리별 판매 성과는 긍정적인 모멘텀을 보여주었습니다: 상업용 API 판매는 5.8% 증가하여 CHF 327.0 백만에 이르고, CMC 개발은 3.0% 증가하여 CHF 234.4 백만에, 연구 및 전문 분야는 7.5% 증가하여 CHF 43.8 백만에 이르렀습니다.
회사는 2024년에 능력 확장을 위해 CHF 292.2 백만을 투자했으며, 2025년 2분기에 시험 배치 생산을 시작할 예정인 'K'의 건설 진행도 포함됩니다. 바켐은 2025년 현지 통화로 10-15% 성장 목표를 세우고 있으며, 계획된 CAPEX 투자는 CHF 400 백만을 초과할 것으로 예상하고 있습니다. 회사는 2026년까지 연간 매출이 CHF 10억을 초과하고 EBITDA 마진이 30%를 초과하는 것을 목표로 하고 있습니다.
Bachem (SIX: BANB) a annoncé de solides résultats financiers pour 2024, avec des ventes de groupe en hausse de 4,8 % à CHF 605,3 millions et un EBITDA en augmentation de 5,7 % à CHF 176,3 millions. L'entreprise a atteint une marge EBITDA de 29,1 % et une croissance du bénéfice net de 7,5 % à CHF 120,2 millions.
Les performances des ventes par catégorie ont montré une dynamique positive : les ventes d'API commerciales ont augmenté de 5,8 % à CHF 327,0 millions, le développement CMC a progressé de 3,0 % à CHF 234,4 millions, et la recherche & spécialités a augmenté de 7,5 % à CHF 43,8 millions.
L'entreprise a investi CHF 292,2 millions dans l'expansion de sa capacité en 2024, y compris des avancées dans la construction de 'K' à Bubendorf, qui devrait commencer la production de lots d'essai au deuxième trimestre 2025. Bachem vise une croissance de 10 à 15 % en monnaies locales pour 2025, avec des investissements CAPEX prévus dépassant CHF 400 millions. L'entreprise vise à atteindre des ventes annuelles de plus de CHF 1 milliard avec une marge EBITDA supérieure à 30 % d'ici 2026.
Bachem (SIX: BANB) hat für 2024 starke Finanzzahlen gemeldet, mit einem Anstieg des Gruppenumsatzes um 4,8% auf CHF 605,3 Millionen und einem EBITDA-Anstieg um 5,7% auf CHF 176,3 Millionen. Das Unternehmen erzielte eine EBITDA-Marge von 29,1% und ein Wachstum des Nettogewinns von 7,5% auf CHF 120,2 Millionen.
Die Verkaufsleistung in den Kategorien zeigte einen positiven Trend: Die Verkäufe von kommerziellen APIs stiegen um 5,8% auf CHF 327,0 Millionen, die CMC-Entwicklung wuchs um 3,0% auf CHF 234,4 Millionen und Forschung & Spezialitäten stiegen um 7,5% auf CHF 43,8 Millionen.
Das Unternehmen investierte 292,2 Millionen CHF in die Kapazitätserweiterung im Jahr 2024, einschließlich Fortschritte beim Bau von 'K' in Bubendorf, das voraussichtlich im 2. Quartal 2025 mit der Testbatch-Produktion beginnen wird. Bachem strebt für 2025 ein Wachstum von 10-15% in lokalen Währungen an, mit geplanten CAPEX-Investitionen von über 400 Millionen CHF. Das Unternehmen zielt darauf ab, bis 2026 einen Jahresumsatz von über 1 Milliarde CHF mit einer EBITDA-Marge von über 30% zu erreichen.
- Sales growth of 4.8% to CHF 605.3M
- EBITDA increase of 5.7% to CHF 176.3M
- Net income growth of 7.5% to CHF 120.2M
- Commercial API sales up 5.8%
- Dividend increase of CHF 0.05 to CHF 0.85 per share
- Strong order volume reported
- EBIT margin declined to 22.0% from 22.4% in 2023
- Higher depreciation and amortization costs impacting margins
Ad hoc announcement pursuant to Art. 53 LR
| Media Release |
Bachem increases sales and profitability
- Group sales rise to CHF 605.3 million (+
4.8% ) in 2024. - EBITDA increases to CHF 176.3 million (+
5.7% ). - EBITDA margin lies at
29.1% . - In local currencies sales rise by
5.6% and EBITDA increases by7.7% to a margin of29.4% . - Board of Directors proposes an increase of the dividend by CHF 0.05 to CHF 0.85 per share.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10552/242623_figure1.png
Thomas Meier, CEO of Bachem, on the results of fiscal year 2024:
"Thanks to a strong order volume and efficiency measures on existing equipment, we were able to reach our financial targets in 2024 and once again increase sales and profit. At the same time, we are vigorously building up new capacity in order to manufacture peptides at ton-scale for medicines in urgent demand. With over 2 200 dedicated colleagues, we are very confident that we will successfully master this largest expansion and change process in our company’s history."
Group results
Bubendorf, Switzerland--(Newsfile Corp. - February 27, 2025) - The Bachem Group (SIX: BANB) increased sales in Swiss francs by
Operating income before depreciation and amortization (EBITDA) increased by
Operating income (EBIT) rose by
Net income grew to CHF 120.2 million (+
Sales by product category
Bachem achieved sales of CHF 327.0 million (2023: CHF 309.0 million, +
In the clinical medicines category (CMC Development), sales increased to CHF 234.4 million (2023: CHF 227.5 million, +
Business with research chemicals and specialty products (Research & Specialties) grew to CHF 43.8 million (2023: CHF 40.8 million, +
Substantial capacity expansion
Bachem is pursuing an investment program to expand capacity at all sites. CHF 292.2 million were invested in 2024. In addition to expansion, Bachem is also continuously optimizing the utilization of existing buildings and facilities to achieve operational improvements.
Bachem began construction of the world's most advanced production plant for large volumes of peptides and oligonucleotides in 2021 (building “K”) in Bubendorf. The first manufacturing equipment in the building is in commissioning and qualification. Transition to the production of first test batches is intended to take place as planned from the 2nd quarter of 2025. The successful ramp-up of commercial production in the building is a key prerequisite for achieving the revenue target in 2026.
For a further manufacturing site planned in Sisslerfeld in the Swiss municipality of Eiken, Bachem purchased a third portion of land in the first half of 2024. Bachem intends to refine a site development plan (“Entwicklungsrichtplan”) for the authorities ahead of pursuing first construction applications in 2025.
Bachem continues to invest in its entire network of sites, focusing on site-specific core competencies. In the US, high-volume capacity at the Vista site is being expanded. In Torrance, Bachem is focusing on promising small-volume clinical projects, while investments at the Vionnaz site in Western Switzerland are aimed at securing the supply of key precursors.
Outlook
For 2025 Bachem expects growth in local currencies between
The complete Annual Report 2024 can be viewed and downloaded on the Bachem website:
https://www.bachem.com/about-bachem/investors-and-media/reports-and-presentations/
Financial Calendar
| April 30, 2025 May 7, 2025 July 24, 2025 March 12, 2026 | Annual General Meeting (business year 2024) Payout date for dividend Publication of Half-Year Report 2025 Publication of Annual Report 2025; Media and Analyst conference |
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
For more information:
Media
Dr. Daniel Grotzky
Head Group Communications
Tel.: +41 58 595 2021
Email: media@bachem.com
Investors
Barbora Blaha
Head Investor Relations
Tel.: +41 58 595 0573
Email: ir@bachem.com
This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242623
FAQ
What were Bachem's (BCHMY) key financial metrics for 2024?
How much is Bachem investing in capacity expansion for 2025?
What are Bachem's revenue and margin targets for 2026?
When will Bachem's new Building K facility begin test batch production?
What is Bachem's growth forecast for 2025?
